A Study of Pharmacogenomics (PGx) Results and Clinical Data of Chronic Pain Patients to Assess Current and Future Therapeutic Relevance
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 17-004473
Sponsor Protocol Number: 17-004473
About this study
The purpose of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for a group of chronic pain patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria
- A Mayo Clinic patient within the Pain Division piloting PGx testing with the Center for Individualized Medicine, seeking clinical information from emerging PGx testing technologies available in CLIA/CAP laboratories
- Patient age 18 or above
- Patient must reside in a county within a 100 mile radius of Rochester, MN
- Patient must be taking a medication of interest (classes of medications include TCA, SNRI, opioid, or benzodiazepine)
- Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures
- Patient is willing to engage in a medication assessment as part of their clinical visit preparation (when needed)
Exclusion Criteria
- Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator William Mauck, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available